Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:dapagliflozin
gptkb:saxagliptin metformin hydrochloride |
| gptkbp:ATCCode |
A10BD23
|
| gptkbp:contraindication |
severe renal impairment
history of hypersensitivity to components |
| gptkbp:form |
extended-release tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Qternmet XR
|
| gptkbp:manufacturer |
gptkb:AstraZeneca
|
| gptkbp:mechanismOfAction |
biguanide
SGLT2 inhibitor DPP-4 inhibitor |
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:regulates |
approved
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:hypoglycemia
urinary tract infection gastrointestinal upset |
| gptkbp:usedFor |
gptkb:type_2_diabetes_mellitus
|
| gptkbp:bfsParent |
gptkb:AstraZeneca_US
|
| gptkbp:bfsLayer |
6
|